Active Surveillance for Localized Prostate Cancer: A New Paradigm for Clinical Management will serve as a useful resource for physicians dealing with, and interested in, this complex and evolving branch of prostate cancer management. The book will also be of interest to scientifically literate patients and their families. The volume provides an introduction to the concept of active surveillance in oncology in general and prostate cancer specifically. The primary focus is to provide a comprehensive guide to the management of patients on surveillance. The volume covers the many complexities and nuances to this approach including, patient selection, risk assessment, how to overcome 'cancer hysteria' when counseling patients, identifying appropriate triggers for intervention, use of PSA kinetics and MR imaging information, technique and frequency of biopsies, secondary prevention interventions, and the relative roles of surveillance and focal therapy.
Reviews / Votes
From the reviews:
"The concept of active surveillance (AS) was developed by Klotz, with the aim of limiting the risk of overtreatment in patients with low-risk cancers, while providing timely radical treatment for those requiring it. Currently, this concept is supported by an increasing number of urologists. . This excellent overview dedicated to AS fills a lack in the literature. . this textbook can be recommended to all physicians involved in prostate cancer management." (European Urology Today, Vol. 25 (2), March-May, 2013)
"This book summarizes the current worldwide experience with active surveillance for prostate cancer. . this book is appropriate for primary care physicians, surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, psychiatrists, and psychologists. Furthermore, it would be valuable to the general audience and patients as it clearly describes the role and implications of active surveillance in the treatment of prostate cancer. . I strongly recommend this book to any clinician whose practice involves the treatment of patients with prostate cancer in any capacity." (Sanjay Kasturi, Doody's Book Reviews, October, 2012)
Series
Edition
Language
Place of publication
Target group
Professional and scholarly
Professional/practitioner
Illustrations
18 s/w Tabellen, 22 farbige Abbildungen, 11 s/w Abbildungen
18 Tables, black and white; 22 Illustrations, color; 11 Illustrations, black and white; XI, 208 p. 33 illus., 22 illus. in color.
Dimensions
Height: 25.4 cm
Width: 17.8 cm
Weight
ISBN-13
978-1-61779-911-2 (9781617799112)
DOI
10.1007/978-1-61779-912-9
Schweitzer Classification
Chapter 1. The Problem of Cancer Overdiagnosis and Overtreatmentby Laurence KlotzChapter 2. Patient Selection for Active Surveillanceby John Eifler and H. Ballentine CarterChapter 3. Predicting High Risk Disease Using Tissue Biomarkersby Michael J. Donovan and Carlos Cordon-CardoChapter 4. Predicting High Risk Disease Using Serum and DNA Biomarkersby Danny Vesprini and Robert NamChapter 5. Triggers for Intervention in Men on Surveillanceby S.Y. Jackie Sham and Chris ParkerChapter 6. The Role of MRI in Active Surveillance by Caroline M. Moore, Clare Allen, Mark EmbertonChapter 7. Active Surveillance: The European Experienceby Meelan Bul, Monique J. Roobol and Chris H. Bangma Chapter 8. Active Surveillance: The Canadian Experienceby Laurence KlotzChapter 9. Psychosocial Aspects of Active Surveillanceby Meredith Wallace Kazer, Dwanna M. Ward-Boahen, David M. Latini, Donald E. Bailey, Jr.Chapter 10. Statistical Considerations for Patient Selection and Triggers for Intervention in Active Surveillanceby Andrew J. VickersChapter 11. Interpreting PSA Kinetics using GLMM Techniqueby Liying Zhang and Laurence KlotzChapter 12. The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancerby Stacey A. Kenfield, J. Kellogg Parsons, June M. ChanChapter 13. The Role of 5a-Reductase Inhibitors (5-ARIs) in Expectant Management of Low Risk Prostate Cancer by David Margel and Neil FleshnerChapter 14. Urologists' Opinion on Active Surveillance: United States vs. the Netherlands by Lionne D.F. Venderbos, Chris H. Bangma, Ida J. Korfage Chapter 15. Clinical 'Pearls' in Managing Patients on Surveillanceby Laurence KlotzChapter 16. Active Surveillance, Focal Therapy and the Futureby Mark EmbertonChapter 17. The Economics of Active Surveillance for Prostate Cancerby Marc A. Dall'Era and Christopher P. EvansChapter 18. The Future of Active Surveillanceby Sima P. Porten, Jared M. Whitson, Peter R. Carroll
